CoQ10
Ubiquinone / Ubiquinol
CoQ10 (Ubiquinone / Ubiquinol) is a longevity & bioregulators research compound. Electron-transport-chain carrier and lipid antioxidant central to mitochondrial ATP production.
CoQ10 quick facts
| Reported research dose | 50mg-200mg |
| Route | Either |
| Frequency | 1x Daily AM · Every Other Day or Daily |
| Half-life | Long (tissue) |
| Forms | Injectable |
| Evidence level | Human (supplement) |
Foundational mitochondrial support. Injectable chases absorption most people miss orally.
How CoQ10 works
Electron-transport-chain carrier and lipid antioxidant central to mitochondrial ATP production.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get CoQ10
Buy CoQ10 at Disguised Alpha →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for CoQ10
Graded by what exists behind each claim.
✅ Clinically validated
- Randomized trials exist and are mixed by indication. The strongest is Q-SYMBIO (420 patients, 2 years) in chronic heart failure, which reported reduced major adverse cardiovascular events and mortality — a positive hard outcome from a supplement, which is rare enough to note.
- Statin-associated muscle symptoms are where it is most used and least supported — meta-analyses of CoQ10 for statin myalgia are inconsistent and largely unimpressive despite a clean mechanistic rationale.
- Trials in migraine prophylaxis and in male fertility report modest benefit; trials in Parkinson's disease at high dose were stopped for futility.
📊 Correlative data
- Very wide oral use. Absorption is the practical issue — it is large, fat-soluble and poorly absorbed, which is why it should be taken with fat and why the ubiquinol form is often preferred.
- The injectable route in this Vault sidesteps the absorption problem entirely, which is its whole rationale and also means the oral trial data does not directly transfer.
🧪 Theoretical / extrapolated
- Carries electrons between complexes I/II and III in the mitochondrial electron transport chain — no CoQ10, no oxidative phosphorylation. It is also a lipid-phase antioxidant protecting membranes from peroxidation.
- It is synthesized through the mevalonate pathway, the same one statins block, which is the mechanistic basis for the statin-myalgia hypothesis and explains why the idea persists despite unconvincing trials.
- Levels decline with age and are lowest in the most metabolically active tissue — heart, liver, kidney — which is a coherent explanation for why the clearest positive trial was in heart failure specifically.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What CoQ10 actually does
Coenzyme Q10 is the only lipid-soluble electron carrier in the inner mitochondrial membrane, and its chemistry is a two-electron redox couple that has to happen inside a membrane it is dissolved in. Ubiquinone (oxidized) accepts electrons from complex I and from complex II, becomes ubiquinol (reduced), diffuses laterally through the lipid bilayer, and hands them to complex III. It also accepts electrons from electron-transferring flavoprotein dehydrogenase, which is the entry point for fatty acid beta-oxidation — so a molecule sold for energy is genuinely the junction where fat oxidation joins the respiratory chain.
The second job is antioxidant and it is the reason the reduced form is sold at a premium. Ubiquinol is the only lipid-soluble antioxidant the body synthesizes itself, and it terminates lipid peroxidation chains within membranes and within LDL particles. The comparison between the two forms as a supplement has been reviewed directly Fladerer 2023, and the honest summary is that the body interconverts them, so which form you swallow matters mainly for absorption rather than for what arrives.
Here is the fact that should reorganize how anybody thinks about this supplement: CoQ10 travels in blood on lipoproteins, overwhelmingly on LDL. It is a 50-carbon isoprenoid tail attached to a quinone head; it is not water-soluble, so it cannot circulate free. It is packaged with cholesterol and it goes where cholesterol goes. Which means any drug that lowers LDL particle number lowers measured plasma CoQ10, by lowering the carrier, without necessarily lowering the CoQ10 inside any tissue. The entire statin-depletes-CoQ10 argument rests on a plasma measurement that is confounded by its own carrier, and almost nobody states this.
And the third thing, which is the one the vendors cannot fix. CoQ10 is synthesized in situ, in the mitochondrion, through a long biosynthetic pathway that starts from tyrosine and the mevalonate isoprenoid chain. Cells make it where they use it. Getting an exogenous molecule from a lipoprotein in the plasma, across the plasma membrane, through the cytosol and into the inner mitochondrial membrane of a specific tissue is a delivery problem that remains explicitly unresolved — bioavailability, administration route, blood-brain barrier penetration and cellular transport are all named as open issues in the current review Mantle 2023.
Cell, rodent, human — and where it stops
Step one, plasma. This step always works, and it is the step every marketing claim stops at. Oral CoQ10 raises plasma CoQ10. Formulation changes how much: solubilized, phytosome and cocrystal preparations all outperform crystalline powder, and the comparison between ubiquinone and ubiquinol has been made directly Fladerer 2023.
Step two, cell uptake — and there is exactly one good experiment, and it is ex vivo. Investigators took CoQ10-enriched low-density lipoproteins from a randomized crossover study in humans and applied them to cells. Uptake was +103% in human dermal fibroblasts and +48% in murine skeletal myoblasts for the phytosome-derived lipoproteins against crystalline CoQ10 — despite equivalent plasma bioavailability Marcheggiani 2023. Read that carefully, because it is the most informative sentence about this supplement anywhere: two products that produce the same plasma level delivered twice as much CoQ10 into a cell. The plasma number that every study reports is therefore not the variable that determines delivery.
Step three, tissue and mitochondrion. This step has not been demonstrated in a person at supplement doses. The review that catalogs the unresolved issues names this explicitly Mantle 2023. Human muscle biopsy studies of CoQ10 supplementation have generally not shown convincing increases in muscle CoQ10 content in people who were not deficient to begin with. That is the honest shape of the chain: plasma yes, cell uptake shown once and ex vivo, mitochondrial incorporation unshown.
Step four, outcomes, where the evidence is genuinely split. Q-SYMBIO randomized patients with chronic heart failure to CoQ10 or placebo and measured morbidity and mortality Mortensen 2014 — a real, positive, randomized outcome trial in a population with a plausible deficit. Against that, on the claim most readers care about: a meta-analysis of 472 patients across 8 studies found that adding CoQ10 for statin-induced myopathy left CK essentially unchanged (mean difference 3.29 U/L; 95% CI -29.58 to 36.17; p=0.84) and did not significantly improve muscle pain (standardized mean difference -0.59; 95% CI -1.54 to 0.36; p=0.22) Wei 2022. A later randomized trial in older adults with statin-associated asthenia did find gains — asthenia -30.0%, handgrip strength +29.8%, two-minute step test +11.1%, one-minute sit-to-stand +36.4% at 8 weeks against placebo, all p<0.05, using a phytosome formulation Fogacci 2024. The difference between those two results may be the formulation, which is exactly what the ex vivo uptake data predicts.
CoQ10 pharmacokinetics — how much of it actually gets in
The card says “long (tissue)”. That is true and it hides the only question that matters, which is whether it reaches the tissue at all.
What clears it. CoQ10 is not cleared by a cytochrome in any meaningful sense; it is a lipid that is taken up with lipoproteins, used, and excreted largely in bile. Its plasma disappearance follows the turnover of the lipoproteins carrying it, which is why the apparent half-life is long — on the order of a day and a half — and why plasma levels take one to two weeks to plateau on a fixed dose and a similar time to fall after stopping.
The oral barrier is the whole story, and it is a solubility problem. CoQ10 is a large, extremely lipophilic molecule of roughly 863 daltons with essentially zero aqueous solubility. Absorption requires bile salt micelles, so oral bioavailability of crystalline powder is very low and is several-fold higher when the dose is taken with a fat-containing meal. Absorption is also saturable, which is why single doses above a few hundred milligrams give diminishing plasma returns and why divided dosing outperforms a single large dose.
The number that reframes the whole category. Two formulations with equivalent plasma bioavailability differed by 103% and 48% in cellular uptake Marcheggiani 2023. Plasma concentration is therefore not a sufficient statistic for this molecule — the lipoprotein it is loaded into changes what a cell does with it. No consumer product reports that variable, and no blood test a reader can order measures it.
The injectable comparator, and why this Vault card raises a question. This page lists the form as injectable. An injected preparation of a molecule with zero aqueous solubility must be a solubilized or emulsified formulation, and the identity of the solubilizing agent then determines both the tolerability and which lipoprotein the CoQ10 ends up on. Since lipoprotein loading is the variable that predicted cellular uptake in the one study that measured it Marcheggiani 2023, an injectable CoQ10 has no published pharmacokinetics and no way to predict its cellular delivery. Bypassing the gut solves the absorption problem and leaves the distribution problem entirely open.
What would have to be true, and how you would know it was not
Three predictions. The second is the one this page exists to make, and the third argues against the commonest reason people buy it.
1. The CoQ10-to-LDL ratio is the measurement, not CoQ10. Order CoQ10 and a lipid panel with ApoB in the same draw, at baseline and at 8 weeks, and compute CoQ10 divided by LDL cholesterol. Because CoQ10 rides on LDL, the raw value moves when the carrier moves. Prediction: the raw CoQ10 rises on supplementation and the ratio rises more, and in anyone starting a statin, the raw value falls while the ratio barely moves. If that holds, the statin-depletion story is substantially a carrier artifact, which is a testable claim that costs one extra checkbox on a requisition.
2. CK should not change, because it did not in the trials. Across 472 patients, adding CoQ10 to statin therapy moved CK by 3.29 U/L with a confidence interval straddling zero and moved muscle pain not at all Wei 2022. Draw a CMP and CK at baseline and 12 weeks. Prediction: flat. Anyone whose symptoms improve with a flat CK has had a symptomatic response, not a myopathy corrected, and that distinction is worth more to a reader than another testimonial. The trial that did find functional gains used handgrip strength and sit-to-stand rather than an enzyme Fogacci 2024, which is the honest way to measure a symptomatic response.
3. The prediction that cuts against it: in a person who is not deficient, nothing should change. Q-SYMBIO worked in chronic heart failure Mortensen 2014, a population with a plausible myocardial deficit. Nothing in the human literature establishes that a healthy person with normal mitochondria and adequate biosynthesis gains anything. The falsifiable version: measure VO2 or handgrip at baseline and 12 weeks in a trained, healthy person. Prediction: no measurable change, and the ex vivo uptake data Marcheggiani 2023 explains why — the delivery step has never been shown to complete.
What nobody has tested yet
Four experiments, and the first one is embarrassingly cheap.
Nobody routinely normalizes CoQ10 to its carrier. The measurement exists, the lipid panel exists, and dividing one by the other is arithmetic. Yet almost every study and every clinic reports raw plasma CoQ10. A retrospective reanalysis of any existing statin cohort with both values would settle the depletion question in an afternoon and it has not been done in a way that reached the public.
Nobody has repeated the lipoprotein-uptake experiment with an injectable. The ex vivo design Marcheggiani 2023 is reproducible: dose a person, harvest their lipoproteins, apply them to cells, count uptake. Running it with an injectable CoQ10 preparation would answer whether the injectable route delivers to cells better than an oral phytosome or merely produces a higher plasma number. That is the exact question the form sold on this page raises, and nobody has asked it.
Nobody has measured muscle CoQ10 before and after in statin-treated humans with a formulation known to load cells. The biopsy is routine, the assay is routine, and the unresolved-issues review names tissue delivery as the open question Mantle 2023. The study has not been run with a modern formulation.
Nobody knows whether the responders are the deficient ones. Q-SYMBIO's population plausibly had a deficit Mortensen 2014; the statin-myopathy meta-analysis pooled everybody and found nothing Wei 2022; the asthenia trial found something in a specific population Fogacci 2024. Stratifying by baseline CoQ10-to-LDL ratio is the obvious next analysis of data that already exists, and it would tell a reader whether they are in the group that has ever benefited.
CoQ10 — its own safety story, not its class's
CoQ10 is one of the genuinely low-risk molecules in the Vault, and the honest safety page for it is short and specific rather than reassuring in general terms.
The interaction that actually matters is warfarin. The quinone head of CoQ10 is structurally related to vitamin K's naphthoquinone, and case reports describe reduced anticoagulant effect. This is a mechanistically plausible interaction rather than a theoretical one, and it is the single interaction worth knowing about for a supplement that is otherwise nearly inert. Anyone anticoagulated should have that conversation with the prescriber, not with a page.
The dose-limiting effect is gastrointestinal and it is a solubility effect. Nausea and loose stools at high doses come from unabsorbed lipid-soluble material passing through, which is also why splitting the dose and taking it with fat both reduce symptoms and increase absorption at the same time. That is one change that improves two things, and it follows from the physical chemistry rather than from tolerance.
The injectable form is where the unknowns are, and they are formulation unknowns rather than molecule unknowns. A water-insoluble 863-dalton lipid delivered by injection requires a solubilizer, and solubilizers — not the CoQ10 — are what cause injection-site reactions and hypersensitivity in this kind of preparation. There is no published pharmacokinetic or safety dataset for injectable CoQ10 at supplement doses. That is the specific gap here, and it is a gap about the vehicle.
What CoQ10 will not do, said once so nobody has to find out expensively. It does not rescue a statin's LDL reduction, it did not lower CK in pooled trials Wei 2022, and it has no established role in a person with normal mitochondrial function. The cost of being wrong here is money and a mild stomach, which is why this page can afford to be blunt about the evidence rather than hedged.
Sources read for this page
- Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO, a randomized double-blind trial. JACC: Heart Failure 2014 · PMID 25282031
- Mantle D, et al. Coenzyme Q10 Metabolism: A Review of Unresolved Issues. International Journal of Molecular Sciences 2023 · PMID 36768907
- Marcheggiani F, et al. CoQ10Phytosomes Improve Cellular Ubiquinone Uptake in Skeletal Muscle Cells: An Ex Vivo Study Using CoQ10-Enriched Low-Density Lipoproteins Obtained in a Randomized Crossover Study. Antioxidants (Basel) 2023 · PMID 37107339
- Wei H, et al. Effects of coenzyme Q10 supplementation on statin-induced myopathy: a meta-analysis of randomized controlled trials. Irish Journal of Medical Science 2022 · PMID 33999383
- Fogacci F, et al. Effect of Coenzyme Q10 on Physical Performance in Older Adults with Statin-Associated Asthenia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. Journal of Clinical Medicine 2024 · PMID 38999304
- Fladerer JP, et al. Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality. Current Cardiology Reports 2023 · PMID 37971634
CoQ10 — safety & side effects
- Well tolerated. GI upset, and insomnia if taken late — it is mildly activating in some people.
- Interacts with warfarin — CoQ10 is structurally similar to vitamin K and can reduce INR. Monitor if you take both.
- Lowers blood pressure modestly. Statins deplete CoQ10, which is the main reason to take it. Take it with fat for absorption.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
CoQ10 — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These act on mitochondrial function, NAD+ availability, sirtuin signaling or cellular clearance. The honest prediction is that acute harm is unlikely and the interesting risks are theoretical and long-range — which is a different shape of risk, not an absence of one.
- Growth and clearance signals cut both ways. Anything that improves the efficiency of cell survival is also improving it for cells you would rather not keep. Anything that pushes clearance hard is doing so indiscriminately.
- The near-term, practical ones: NAD+ precursors and infusions commonly cause flushing and a strong sensation if pushed fast, and several compounds in this class are stimulating enough to disrupt sleep.
What has actually been reported
- Generally well tolerated at studied doses. NAD+ infusion discomfort is rate-dependent and resolves by slowing down.
- The human evidence is mostly short trials with surrogate endpoints — a marker moved, not a life changed. That is worth knowing before you build a decade-long habit on it.
How to reduce the risk
Same mechanism as the prediction.
- Slow the infusion rate. Almost all NAD+ discomfort is rate, not dose. There is no prize for finishing quickly.
- Dose earlier in the day. Several of these are subtly stimulating, and sleep is where most of the repair you are paying for happens.
- Pick an endpoint you can actually measure, and take the baseline before you start. This is the class most prone to spending years on something with no way of knowing whether it did anything.
- Fix the basics first. Sleep, training and bloodwork move the same markers further than anything on this list, and they are free. A longevity compound stacked on four hours of sleep is a rounding error.
What it does to your bloodwork
A fact about the assay.
- There is no NAD+ assay worth ordering clinically. Judge this class on downstream markers — inflammatory markers, lipids, fasting glucose, and whatever your baseline panel showed as out of range.
Don't run this if
- Active malignancy, for the survival-signaling reasoning above.
- Pregnancy — uncharacterized.
The honest unknown
- Whether any of it extends healthspan in humans. Every honest person in this field is running on mechanism and animal data, and this catalog should say so rather than imply otherwise.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
CoQ10 — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What CoQ10 moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — CoQ10 in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside CoQ10
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Coenzyme Q10 | Worth measuring if you're on a statin, which depletes it |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | The context most people are taking it in |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Inflammation baseline |
The Real Cardiovascular Risk panel covers these in one order — 9 markers, $187.60 with the discount applied.
Check results you already have → · All 103 markers A–Z
CoQ10 — frequently asked questions
What is CoQ10?
CoQ10 (Ubiquinone / Ubiquinol) is a longevity & bioregulators research compound. Electron-transport-chain carrier and lipid antioxidant central to mitochondrial ATP production.
Is the full CoQ10 protocol on this page?
The reported research dose is on this page, along with how CoQ10 works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of CoQ10?
CoQ10 has an approximate half-life of Long (tissue), which is part of what determines how often it's dosed.
What's the evidence behind CoQ10?
Current evidence level: Human (supplement). CoQ10 is offered for research purposes only and is not an approved medicine.
What CoQ10 is used for
CoQ10 appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.